Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBMP-2/CPM for Osteoporosis
NCT00752557Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2008
- Primary completion
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of dibotermin alfa in osteoporosis (3 arms), sponsored by Pfizer. Primary endpoints: Change From Baseline in Bone Mineral Density (BMD) Measured by Dual-Energy X-ray Absorptiometry (DXA) at 12 months and Time Course Distribution of Volumetric BMD for the Hip Under Study (HUS) at 12 months. Started Dec 2008; status: completed.
02
Drugs
dibotermin alfa
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00752557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00752557.